Desuden blev det vedtaget at præcisere i produktresuméet, at dosisoptrapninger kun må foretages efter en klinisk vurdering, og at den laveste effektive dosis skal opretholdes af hensyn til risikoen for dosisrelaterede bivirkninger.
Additionally, it was agreed to clarify in the SPC that dose increments should only be made after a clinical evaluation, and that the lowest effective dose should be maintained, given the risk of dose-related adverse effects.